LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Akebia Therapeutics Inc

Cerrado

SectorSanidad

3.96 7.32

Resumen

Variación precio

24h

Actual

Mínimo

3.73

Máximo

3.99

Métricas clave

By Trading Economics

Ingresos

29M

6.1M

Ventas

11M

57M

BPA

0.025

Margen de beneficios

10.66

Empleados

181

EBITDA

20M

14M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+82.93% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

242M

854M

Apertura anterior

-3.36

Cierre anterior

3.96

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

166 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Akebia Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 jun 2025, 14:31 UTC

Ganancias

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 19:36 UTC

Charlas de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 jun 2025, 19:28 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 jun 2025, 18:46 UTC

Charlas de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 jun 2025, 18:02 UTC

Charlas de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 jun 2025, 16:35 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:34 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:21 UTC

Charlas de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

6 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 jun 2025, 16:07 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 jun 2025, 16:07 UTC

Charlas de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 jun 2025, 15:53 UTC

Charlas de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 15:33 UTC

Charlas de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 jun 2025, 15:16 UTC

Charlas de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 jun 2025, 15:05 UTC

Charlas de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 jun 2025, 14:35 UTC

Charlas de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 jun 2025, 14:15 UTC

Charlas de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 jun 2025, 14:12 UTC

Ganancias

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 jun 2025, 14:09 UTC

Ganancias

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparación entre iguales

Cambio de precio

Akebia Therapeutics Inc previsión

Precio Objetivo

By TipRanks

82.93% repunte

Estimación a 12 Meses

Media 6.75 USD  82.93%

Máximo 8 USD

Mínimo 6 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Akebia Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.345 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

166 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.